184 related articles for article (PubMed ID: 26994323)
1. Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia.
Gustine JN; Meid K; Dubeau TE; Treon SP; Castillo JJ
Am J Hematol; 2016 Jun; 91(6):E312-3. PubMed ID: 26994323
[No Abstract] [Full Text] [Related]
2. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Dimopoulos MA; Tedeschi A; Trotman J; García-Sanz R; Macdonald D; Leblond V; Mahe B; Herbaux C; Tam C; Orsucci L; Palomba ML; Matous JV; Shustik C; Kastritis E; Treon SP; Li J; Salman Z; Graef T; Buske C;
N Engl J Med; 2018 Jun; 378(25):2399-2410. PubMed ID: 29856685
[TBL] [Abstract][Full Text] [Related]
3. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib.
Cheng MP; Kusztos AE; Gustine JN; Dryden-Peterson SL; Dubeau TE; Woolley AE; Hammond SP; Baden LR; Treon SP; Castillo JJ; Issa NC
Br J Haematol; 2019 May; 185(4):788-790. PubMed ID: 30460682
[No Abstract] [Full Text] [Related]
4. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
[TBL] [Abstract][Full Text] [Related]
5. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia.
Castillo JJ; Gustine JN; Meid K; Dubeau TE; Xu L; Yang G; Hunter ZR; Advani R; Palomba L; Treon SP
Haematologica; 2018 Oct; 103(10):e466-e468. PubMed ID: 29773590
[No Abstract] [Full Text] [Related]
6. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
[TBL] [Abstract][Full Text] [Related]
7. Concomitant Treatment with Ibrutinib and Amiodarone Causing Reversible Heart Failure Syndrome.
Wasserstrum Y; Raanani P; Kornowski R; Iakobishvili Z
Isr Med Assoc J; 2016 Jul; 18(7):433-434. PubMed ID: 28471569
[No Abstract] [Full Text] [Related]
8. Sudden ventricular fibrillation and death during ibrutinib therapy-A case report.
Bernardeschi P; Pirrotta MT; Del Rosso A; Fontanelli G; Milandri C
Eur J Haematol; 2019 Oct; 103(4):442-443. PubMed ID: 31287200
[TBL] [Abstract][Full Text] [Related]
9. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Boriani G; Corradini P; Cuneo A; Falanga A; Foà R; Gaidano G; Ghia PP; Martelli M; Marasca R; Massaia M; Mauro FR; Minotti G; Molica S; Montillo M; Pinto A; Tedeschi A; Vitolo U; Zinzani PL
Hematol Oncol; 2018 Oct; 36(4):624-632. PubMed ID: 29512173
[TBL] [Abstract][Full Text] [Related]
10. Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.
Fradley MG; Gliksman M; Emole J; Viganego F; Rhea I; Welter-Frost A; Armanious M; Lee DH; Walko C; Shah B; Chavez JC; McLeod H; Pinilla-Ibarz J; Schabath MB
Am J Cardiol; 2019 Aug; 124(4):539-544. PubMed ID: 31208701
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib-induced acute liver failure.
Kahn A; Horsley-Silva JL; Lam-Himlin DM; Reeder CB; Douglas DD; Carey EJ
Leuk Lymphoma; 2018 Feb; 59(2):512-514. PubMed ID: 28693376
[No Abstract] [Full Text] [Related]
12. Ibrutinib therapy for lymphoplasmacytic lymphoma.
Helber MJ; Moore JE; Williams AM; Meacham PJ; Rothberg PG; Zent CS
Am J Hematol; 2017 Sep; 92(9):E542-E544. PubMed ID: 28543765
[No Abstract] [Full Text] [Related]
13. Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib.
Tuomi JM; Xenocostas A; Jones DL
Can J Cardiol; 2018 Mar; 34(3):337-341. PubMed ID: 29475534
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.
Castillo JJ; Gustine JN; Meid K; Dubeau T; Severns P; Treon SP
Haematologica; 2018 Jul; 103(7):e307-e310. PubMed ID: 29472352
[No Abstract] [Full Text] [Related]
15. Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
Ambinder AJ; Hambley B; Shanbhag S; Merrill SA
Am J Hematol; 2019 Nov; 94(11):E296-E299. PubMed ID: 31400009
[No Abstract] [Full Text] [Related]
16. ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
Prescrire Int; 2016 Oct; 25(175):232. PubMed ID: 30645823
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Sanz RG; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous JV; Motta M; Siddiqi T; Tani M; Trneny M; Minnema MC; Buske C; Leblond V; Trotman J; Chan WY; Schneider J; Ro S; Cohen A; Huang J; Dimopoulos M
Blood; 2020 Oct; 136(18):2038-2050. PubMed ID: 32731259
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib-Associated Atrial Fibrillation.
Ganatra S; Sharma A; Shah S; Chaudhry GM; Martin DT; Neilan TG; Mahmood SS; Barac A; Groarke JD; Hayek SS; Dani S; Venesy D; Patten R; Nohria A
JACC Clin Electrophysiol; 2018 Dec; 4(12):1491-1500. PubMed ID: 30573111
[TBL] [Abstract][Full Text] [Related]
19. Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia.
Othman J; Verner E; Tam CS; Huang J; Lin L; Hilger J; Trotman J; Gasiorowski R
Haematologica; 2018 May; 103(5):e223-e225. PubMed ID: 29439186
[No Abstract] [Full Text] [Related]
20. Ibrutinib-related atrial fibrillation: Therapeutic challenges.
Kapelios CJ; Bonou MS; Diamantopoulos P; Angelopoulou MK; Masoura C; Barbetseas J; Viniou NA
J Oncol Pharm Pract; 2019 Jul; 25(5):1258-1260. PubMed ID: 30012045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
